BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33025343)

  • 1. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
    Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
    Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
    Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
    Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.
    Suoh M; Hagihara A; Yamamura M; Maruyama H; Taira K; Enomoto M; Tamori A; Fujiwara Y; Kawada N
    Intern Med; 2021 Feb; 60(4):545-552. PubMed ID: 33028766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
    Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
    Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
    Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
    Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
    Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
    Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
    Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
    Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
    Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
    Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
    Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
    Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
    Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.
    Kim BH; Yu SJ; Kang W; Cho SB; Park SY; Kim SU; Kim DY
    J Gastroenterol Hepatol; 2022 Mar; 37(3):428-439. PubMed ID: 34725855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
    Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
    Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
    Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
    Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
    Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.